Gilead Science尽管面临长期增长问题, 却看到股价势头。 Gilead Sciences beat earnings estimates, raised 2026 guidance, and saw stock momentum despite long-term growth questions.

Gilead Science报告Q4收入丰厚,EPS收入为1.86美元,收入估计数为7.93B美元,并将2026年全年指导提高到8.45-8.85 EPS美元。 Gilead Sciences reported strong Q4 earnings with $1.86 EPS and $7.93B in revenue, beating estimates, and raised its 2026 full-year guidance to $8.45–$8.85 EPS. 包括Wolfe Research和Oppenheimer在内的多个公司提高了价格目标,并列举了其艾滋病毒药物和 Yescarta扩张的势头。 Multiple firms, including Wolfe Research and Oppenheimer, raised price targets, citing momentum in its HIV drugs and Yescarta expansion. 股票交易额为154.98美元,市场上限为192.28B美元,P/E为22.89美元,较低的贝塔为0.36美元,反映了稳定性。 The stock, trading at $154.98, has a market cap of $192.28B, a P/E of 22.89, and a low beta of 0.36, reflecting stability. 机构所有权仍然很高,为83.67%,Cookson Peirce & Co.的股份增加了249%。 Institutional ownership remains high at 83.67%, with Cookson Peirce & Co. increasing its stake by 249%. 尽管对艾滋病毒的长期增长存有疑问,分析员仍保持积极的前景。 Analysts maintain a positive outlook despite questions about long-term HIV growth.